Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and ATL-DC Vaccine in Recurrent Glioblastoma
NCT04201873Phase 1Completed
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- Jan 2020
- Primary completion
- Aug 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised trial in glioblastoma (GBM) comparing Group A (pembrolizumab, ATL-DC, poly ICLC) with Group B (placebo, ATL-DC, poly ICLC) (2 arms). Primary endpoints: Cell cycle-related signature up to 6 years, Expansion of T cell receptor (TCR) clones up to 6 years and 1 more. Started Jan 2020; status: completed.
02
Drugs
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT04201873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04201873.